PMID- 24696007
OWN - NLM
STAT- MEDLINE
DCOM- 20150513
LR  - 20211021
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2014
DP  - 2014
TI  - FC-98 regulates TLR9-mediated of CXCL-10 expression in dendritic cells via MAPK 
      and STAT1 signaling pathway.
PG  - 926130
LID - 10.1155/2014/926130 [doi]
LID - 926130
AB  - Dendritic cells (DCs), as the most potent professional antigen presenting cells, 
      play a crucial role in both innate and adaptive immune systems. Genomic bacterial 
      DNA mimicked by unmethylated CpG motifs is discovered to possess 
      immunostimulatory effects. CpG-DNA recognized by Toll-like receptor 9 (TLR9) on 
      DCs arouses many immune diseases (such as cancer, viral infection, and autoimmune 
      disorders). In this study we investigated the effects of FC-98 on CpG-induced 
      bone marrow-derived DCs (BMDCs). The results showed that FC-98 significantly 
      inhibited the CpG-induced BMDCs maturation and function by suppressing the 
      expression of surface markers (CD40, CD80, CD86, and MHCII). Moreover, FC-98 
      downregulated the expression of C-X-C motif chemokine 10 (CXCL-10) both at the 
      mRNA and protein level after CpG induction. Meanwhile, FC-98 markedly affected 
      the migration of BMDCs to T cells without affecting their endocytosis capacity. 
      Furthermore, FC-98 was confirmed to decrease CXCL-10 expression by inhibiting 
      CpG-induced activation of MAPKs (ERK, JNK, and p38) and STAT1 signaling. Overall, 
      these results suggested that FC-98 was a potential molecule in the treatment of 
      CXCL-10-mediated immune diseases.
FAU - Yang, Yonghong
AU  - Yang Y
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing 210093, China.
FAU - Dou, Huan
AU  - Dou H
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing 210093, China ; Jiangsu Key 
      Laboratory of Molecular Medicine, Nanjing 210093, China.
FAU - Li, Xiaoqin
AU  - Li X
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing 210093, China.
FAU - Song, Yuxian
AU  - Song Y
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing 210093, China.
FAU - Gong, Wei
AU  - Gong W
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing 210093, China.
FAU - Tan, Renxiang
AU  - Tan R
AD  - Institute of Functional Biomolecules, School of Life Sciences, Nanjing 
      University, Nanjing 210093, China.
FAU - Hou, Yayi
AU  - Hou Y
AUID- ORCID: 0000-0002-1152-9132
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing 210093, China ; Jiangsu Key 
      Laboratory of Molecular Medicine, Nanjing 210093, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140217
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (CPG-oligonucleotide)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (N1-((4-fluorophenyl)methyl)-4-methyl-1,2-benzenediamine)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (Phenylenediamines)
RN  - 0 (STAT1 Transcription Factor)
RN  - 0 (Toll-Like Receptor 9)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Bone Marrow Cells/cytology
MH  - Cell Survival/drug effects
MH  - Chemokine CXCL10/*metabolism
MH  - Dendritic Cells/cytology/drug effects/*metabolism
MH  - Endocytosis/drug effects
MH  - Enzyme Activation/drug effects
MH  - MAP Kinase Signaling System/*drug effects
MH  - Mice, Inbred C57BL
MH  - Oligodeoxyribonucleotides/pharmacology
MH  - Phenotype
MH  - Phenylenediamines/chemistry/*pharmacology
MH  - STAT1 Transcription Factor/*metabolism
MH  - Stereoisomerism
MH  - Toll-Like Receptor 9/*metabolism
MH  - Up-Regulation/drug effects
PMC - PMC3947834
EDAT- 2014/04/04 06:00
MHDA- 2015/05/15 06:00
PMCR- 2014/02/17
CRDT- 2014/04/04 06:00
PHST- 2013/10/22 00:00 [received]
PHST- 2013/12/17 00:00 [revised]
PHST- 2013/12/31 00:00 [accepted]
PHST- 2014/04/04 06:00 [entrez]
PHST- 2014/04/04 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
PHST- 2014/02/17 00:00 [pmc-release]
AID - 10.1155/2014/926130 [doi]
PST - ppublish
SO  - Biomed Res Int. 2014;2014:926130. doi: 10.1155/2014/926130. Epub 2014 Feb 17.